Commercial-stage manufacturing key for CDMOs as biotech funding pullback continues, Fujifilm Diosynth CEO says
On the back of reduced funding in early clinical-stage assets, CDMOs need to strengthen their commercial, large-scale manufacturing capabilities for 2024 in what looks like another challenging year for manufacturers, Fujifilm Diosynth CEO Lars Petersen said.
“I think the biggest hurdle is how to adjust to the slowdown of venture capitalists funding startups. It will come back, but when it’ll come back — nobody knows,” Petersen told Endpoints News in an interview. “[Fujifilm Diosynth] especially sees large-scale commercial booming, there is still a huge demand…and it’s often from companies who already have a revenue, and they don’t necessarily need a lot of venture capitalist funding,” he explained.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.